Cargando…
Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial
IMPORTANCE: Psoriasis relapse may involve compensatory T-cell activation pathways in the presence of CD28-CD80/CD86 blockade with abatacept. OBJECTIVE: To determine whether costimulatory signaling blockade with abatacept prevents psoriasis relapse after ustekinumab withdrawal. DESIGN, SETTING, AND P...
Autores principales: | Harris, Kristina M., Smilek, Dawn E., Byron, Margie, Lim, Noha, Barry, William T., McNamara, James, Garcet, Sandra, Konrad, Robert J., Stengelin, Martin, Bathala, Pradeepthi, Korman, Neil J., Feldman, Steven R., Boh, Erin E., Barber, Kirk, Laumann, Anne E., Helfrich, Yolanda Rosi, Krueger, Gerald G., Sofen, Howard, Bissonnette, Robert, Krueger, James G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515260/ https://www.ncbi.nlm.nih.gov/pubmed/34643650 http://dx.doi.org/10.1001/jamadermatol.2021.3492 |
Ejemplares similares
-
Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab
por: Campbell, Kim, et al.
Publicado: (2023) -
Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017) -
Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009) -
Costimulatory pathways in transplantation
por: Pilat, Nina, et al.
Publicado: (2011) -
Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)